Literature DB >> 11929052

Ferrochelatase gene mutations in erythropoietic protoporphyria: focus on liver disease.

Fu-Ping Chen1, Hiba Risheg, Yunying Liu, Joseph Bloomer.   

Abstract

A deficiency of ferrochelatase (FECH) activity underlies the excess accumulation of protoporphyrin that occurs in erythropoietic protoporphyria (EPP). In some patients, protoporphyrin accumulation causes liver damage that necessitates liver transplantation. The purpose of this study was to determine if specific mutations in the FECH gene are present in patients who develop liver disease. FECH cDNA and all 11 exons and their flanking intron regions in the FECH gene were amplified and sequenced by specific polymerase chain reactions. Gene mutations were determined in 34 individuals from 24 families: 14 had liver disease, 10 necessitating liver transplantation. All individuals were heterozygous for mutations that altered the coding region of FECH mRNA. The mutations in patients with liver disease were heterogenous, but usually caused a major structural alterations in the FECH protein, most commonly as a result of exon skipping in FECH mRNA. However, the mutations could not account for the severe phenotype by themselves, since the same mutations were found in asymptomatic family members of patients with liver disease and in patients from families in which liver disease was not present. Other genetic factors, and possibly acquired factors, also must be critical to the development of this severe phenotype in EPP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11929052

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  13 in total

1.  The diagnosis and management of erythropoietic protoporphyria.

Authors:  Manish Thapar; Herbert L Bonkovsky
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-08

Review 2.  Liver disease in erythropoietic protoporphyria: insights and implications for management.

Authors:  A V Anstey; R J Hift
Journal:  Postgrad Med J       Date:  2007-12       Impact factor: 2.401

Review 3.  Liver disease in erythropoietic protoporphyria: insights and implications for management.

Authors:  A V Anstey; R J Hift
Journal:  Gut       Date:  2007-03-14       Impact factor: 23.059

4.  Paralytic ileus and liver failure--an unusual presentation of advanced erythropoietic protoporphyria.

Authors:  Simone Negrini; Gabriele Zoppoli; Maurizio Setti; Maria Domenica Cappellini; Francesco Indiveri
Journal:  Dig Dis Sci       Date:  2008-11-14       Impact factor: 3.199

5.  Abnormal mitoferrin-1 expression in patients with erythropoietic protoporphyria.

Authors:  Yongming Wang; Nathaniel B Langer; George C Shaw; Guang Yang; Liangtao Li; Jerry Kaplan; Barry H Paw; Joseph R Bloomer
Journal:  Exp Hematol       Date:  2011-05-11       Impact factor: 3.084

6.  Is it possible for Fe2+ to approach protoporphyrin IX from the side of Tyr-13 in Bacillus subtilis ferrochelatase? An answer from QM/MM study.

Authors:  Yaxue Wang; Yong Shen
Journal:  J Mol Model       Date:  2012-10-25       Impact factor: 1.810

Review 7.  Mitochondrial Iron in Human Health and Disease.

Authors:  Diane M Ward; Suzanne M Cloonan
Journal:  Annu Rev Physiol       Date:  2018-11-28       Impact factor: 19.318

8.  Investigation by MD simulation of the key residues related to substrate-binding and heme-release in human ferrochelatase.

Authors:  Yaxue Wang; Jingheng Wu; Jinqian Ju; Yong Shen
Journal:  J Mol Model       Date:  2013-02-28       Impact factor: 1.810

9.  Level of expression of the nonmutant Ferrochelatase allele is a determinant of biochemical phenotype in a mouse model of erythropoietic protoporphyria.

Authors:  Joseph Bloomer; Yongming Wang; Dongquan Chen
Journal:  Gene Regul Syst Bio       Date:  2008-05-29

Review 10.  Erythropoietic protoporphyria.

Authors:  Mario Lecha; Hervé Puy; Jean-Charles Deybach
Journal:  Orphanet J Rare Dis       Date:  2009-09-10       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.